$CCEL
CRYO CELL INTERNATIONAL INC

2017 Q4 Form 10-Q Financial Statement

#000119312517310883 Filed on October 16, 2017

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2016 Q3
Revenue $6.470M $6.896M $6.332M
YoY Change 10.22% 8.91% 16.48%
Cost Of Revenue $1.640M $1.977M $1.551M
YoY Change 13.89% 27.48% 2.91%
Gross Profit $4.840M $4.918M $4.781M
YoY Change 9.26% 2.88% 21.69%
Gross Profit Margin 74.81% 71.32% 75.5%
Selling, General & Admin $3.540M $3.433M $3.912M
YoY Change -7.09% -12.24% 48.79%
% of Gross Profit 73.14% 69.79% 81.82%
Research & Development $20.00K $226.00 $13.78K
YoY Change 0.0% -98.36% 38.46%
% of Gross Profit 0.41% 0.0% 0.29%
Depreciation & Amortization $60.00K $60.00K $70.00K
YoY Change -14.29% -14.29% 16.67%
% of Gross Profit 1.24% 1.22% 1.46%
Operating Expenses $3.590M $3.433M $3.925M
YoY Change -6.99% -12.55% 48.75%
Operating Profit $1.250M $1.452M -$1.062M
YoY Change 119.3% -236.74% -184.0%
Interest Expense -$370.0K $314.9K $199.4K
YoY Change 164.29% 57.89% -43.59%
% of Operating Profit -29.6% 21.68%
Other Income/Expense, Net -$20.00K -$309.7K -$2.481M
YoY Change -166.67% -87.52% 579.75%
Pretax Income $860.0K $1.143M -$3.543M
YoY Change 145.71% -132.25% -494.5%
Income Tax $180.0K $490.6K -$898.8K
% Of Pretax Income 20.93% 42.93%
Net Earnings $680.0K $652.0K -$2.644M
YoY Change -16.05% -124.66% -133.77%
Net Earnings / Revenue 10.51% 9.46% -41.76%
Basic Earnings Per Share $0.09 -$0.35
Diluted Earnings Per Share $89.24K $0.08 -$0.35
COMMON SHARES
Basic Shares Outstanding 7.103M shares 7.100M shares 7.584M shares
Diluted Shares Outstanding 7.795M shares 7.584M shares

Balance Sheet

Concept 2017 Q4 2017 Q3 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.720M $5.190M $2.660M
YoY Change 63.11% 95.11% -16.35%
Cash & Equivalents $6.279M $4.667M $2.026M
Short-Term Investments $440.0K $520.0K $630.0K
Other Short-Term Assets $206.1K $183.1K $46.84K
YoY Change 162.77% 290.96% 38.16%
Inventory $314.6K $335.8K $410.9K
Prepaid Expenses $372.2K $406.1K $472.1K
Receivables $5.126M $4.861M $4.381M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $12.74M $10.98M $10.15M
YoY Change 41.33% 8.2% 2.4%
LONG-TERM ASSETS
Property, Plant & Equipment $882.4K $888.9K $993.4K
YoY Change -9.91% -10.52% 13.1%
Goodwill $0.00 $0.00 $111.4K
YoY Change -100.0% -93.6%
Intangibles $226.4K $235.1K $266.8K
YoY Change -13.25% -11.9% -52.82%
Long-Term Investments $0.00
YoY Change -100.0%
Other Assets $10.29M $9.451M $6.404M
YoY Change 7.79% 47.59% -25.97%
Total Long-Term Assets $11.17M $10.34M $7.397M
YoY Change 6.14% 39.78% -22.37%
TOTAL ASSETS
Total Short-Term Assets $12.74M $10.98M $10.15M
Total Long-Term Assets $11.17M $10.34M $7.397M
Total Assets $23.91M $21.32M $17.54M
YoY Change 22.37% 21.52% -9.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.929M $1.363M $1.605M
YoY Change 29.83% -15.09% 10.84%
Accrued Expenses $2.582M $1.826M $1.719M
YoY Change 1.1% 6.23% -10.41%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.000M $2.000M $2.000M
YoY Change 0.0% 0.0% 566.67%
Total Short-Term Liabilities $13.94M $12.60M $12.41M
YoY Change 6.32% 1.49% 18.74%
LONG-TERM LIABILITIES
Long-Term Debt $1.425M $1.425M $1.425M
YoY Change 0.0% 0.0% -38.04%
Other Long-Term Liabilities $22.47M $22.12M $22.15M
YoY Change 2.89% -0.1% 60.35%
Total Long-Term Liabilities $23.90M $23.55M $23.57M
YoY Change 2.72% -0.09% 46.3%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.94M $12.60M $12.41M
Total Long-Term Liabilities $23.90M $23.55M $23.57M
Total Liabilities $36.41M $34.72M $34.56M
YoY Change 4.18% 0.47% 30.09%
SHAREHOLDERS EQUITY
Retained Earnings -$24.47M -$25.15M -$27.60M
YoY Change -8.64% -8.86% 9.31%
Common Stock $31.50M $31.23M $29.51M
YoY Change 3.4% 5.8% 4.15%
Preferred Stock
YoY Change
Treasury Stock (at cost) $19.57M $19.57M $18.99M
YoY Change 2.34% 3.08% 135.58%
Treasury Stock Shares 5.801M shares 5.801M shares 5.678M shares
Shareholders Equity -$12.50M -$13.40M -$17.02M
YoY Change
Total Liabilities & Shareholders Equity $23.91M $21.32M $17.54M
YoY Change 22.37% 21.52% -9.74%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2016 Q3
OPERATING ACTIVITIES
Net Income $680.0K $652.0K -$2.644M
YoY Change -16.05% -124.66% -133.77%
Depreciation, Depletion And Amortization $60.00K $60.00K $70.00K
YoY Change -14.29% -14.29% 16.67%
Cash From Operating Activities $2.110M $1.230M $1.080M
YoY Change -17.9% 13.89% 4.85%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K -$60.00K -$10.00K
YoY Change 0.0% 500.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities $30.00K -$10.00K $20.00K
YoY Change -200.0% -150.0% -108.7%
Cash From Investing Activities -$20.00K -$60.00K $10.00K
YoY Change -71.43% -700.0% -104.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -480.0K -1.200M -3.580M
YoY Change -52.94% -66.48% 79.9%
NET CHANGE
Cash From Operating Activities 2.110M 1.230M 1.080M
Cash From Investing Activities -20.00K -60.00K 10.00K
Cash From Financing Activities -480.0K -1.200M -3.580M
Net Change In Cash 1.610M -30.00K -2.490M
YoY Change 8.78% -98.8% 107.5%
FREE CASH FLOW
Cash From Operating Activities $2.110M $1.230M $1.080M
Capital Expenditures -$40.00K -$60.00K -$10.00K
Free Cash Flow $2.150M $1.290M $1.090M
YoY Change -17.62% 18.35% 4.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2011Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000 shares
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6000000 shares
CY2016Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
8000000 shares
CY2017Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7102691 shares
CY2012Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000 shares
CY2016Q2 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
9866178
CY2016Q2 ccel Repurchases Agreement Settlement Payment In Part Through Term Loan
RepurchasesAgreementSettlementPaymentInPartThroughTermLoan
8000000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2026199
CY2016Q3 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
1666430
CY2016Q3 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2016Q3 ccel Intangible Asset Impaired Accumulated Impairment Loss
IntangibleAssetImpairedAccumulatedImpairmentLoss
211267
CY2017Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2086384
CY2017Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1826361
CY2017Q3 us-gaap Assets Current
AssetsCurrent
10976898
CY2017Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4861002
CY2017Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
31097254
CY2017Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1363193
CY2017Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
95086
CY2017Q3 us-gaap Assets
Assets
21316811
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4667083
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7097691 shares
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12893267 shares
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
128932
CY2017Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
7406679
CY2017Q3 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
378785
CY2017Q3 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
9187070
CY2017Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2301000
CY2017Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
14932709
CY2017Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
235063
CY2017Q3 us-gaap Goodwill
Goodwill
0
CY2017Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
235063
CY2017Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
194943
CY2017Q3 us-gaap Inventory Net
InventoryNet
335757
CY2017Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2017Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
123232
CY2017Q3 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2017Q3 us-gaap Liabilities
Liabilities
34720561
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21316811
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
12596233
CY2017Q3 us-gaap Long Term Debt
LongTermDebt
7766619
CY2017Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
5766619
CY2017Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1425000
CY2017Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
523878
CY2017Q3 us-gaap Notes Payable
NotesPayable
8000100
CY2017Q3 us-gaap Notes Payable Current
NotesPayableCurrent
2000000
CY2017Q3 us-gaap Other Assets Current
OtherAssetsCurrent
183117
CY2017Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9451021
CY2017Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22124328
CY2017Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2017Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
406061
CY2017Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
888892
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25153909
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
2.18
CY2017Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1044697 shares
CY2017Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1130229 shares
CY2017Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
2.47
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
85532 shares
CY2017Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
2.34
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
-13403750
CY2017Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
5801086 shares
CY2017Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
233481
CY2017Q3 us-gaap Treasury Stock Value
TreasuryStockValue
19571113
CY2017Q3 ccel Deposits And Other Assets
DepositsAndOtherAssets
28888
CY2017Q3 ccel Reserves Recorded Under Programs
ReservesRecordedUnderPrograms
18000
CY2017Q3 ccel Inventory Collection Kits
InventoryCollectionKits
25300
CY2017Q3 ccel Number Of Employee Stock Based Compensation Plan
NumberOfEmployeeStockBasedCompensationPlan
2 CompensationPlan
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4152162
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2278862
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2554330
CY2016Q4 us-gaap Assets Current
AssetsCurrent
9011923
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4052728
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
30340573
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1485430
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
34408
CY2016Q4 us-gaap Assets
Assets
19538468
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3499881
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6789596 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12504464 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
125044
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
7071924
CY2016Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
9260582
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2301000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
12596292
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
261000
CY2016Q4 us-gaap Goodwill
Goodwill
0
CY2016Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
111392
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
261000
CY2016Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
261000
CY2016Q4 us-gaap Inventory Net
InventoryNet
361142
CY2016Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2016Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
9100
CY2016Q4 us-gaap Liabilities
Liabilities
34952726
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19538468
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13111684
CY2016Q4 us-gaap Long Term Debt
LongTermDebt
9819750
CY2016Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
7819750
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1425000
CY2016Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
624223
CY2016Q4 us-gaap Notes Payable
NotesPayable
10150100
CY2016Q4 us-gaap Notes Payable Current
NotesPayableCurrent
2000000
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
78448
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9547082
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
21841042
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
395501
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
979463
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-26789791
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.84
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
97406 shares
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-15414258
CY2016Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
5714868 shares
CY2016Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
330350
CY2016Q4 us-gaap Treasury Stock Value
TreasuryStockValue
19124492
CY2016Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
25500
CY2016Q4 ccel Reserves Recorded Under Programs
ReservesRecordedUnderPrograms
17000
CY2016Q4 ccel Inventory Collection Kits
InventoryCollectionKits
98760
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2012Q1 ccel Additional Payment Warranty
AdditionalPaymentWarranty
10000
CY2017Q2 ccel Increased Payment Warranty
IncreasedPaymentWarranty
100000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
222513
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
821000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
38252
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2125963
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2244507
us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
145000
us-gaap Cost Of Services
CostOfServices
4330622
us-gaap Costs And Expenses
CostsAndExpenses
17280461
us-gaap Depreciation And Amortization
DepreciationAndAmortization
123166
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-186175
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-64723
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
44327
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2827268
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-842000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-2252388
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
300593
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
1877697
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1505950
us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
-842000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1901591
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-697103
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
449541
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-41554
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-204344
us-gaap Interest Expense
InterestExpense
804236
us-gaap Interest Expense Debt
InterestExpenseDebt
22265
us-gaap Licenses Revenue
LicensesRevenue
965977
us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
3400000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-297184
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
2424902
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-4253681
us-gaap Net Income Loss
NetIncomeLoss
-2130165
us-gaap Operating Income Loss
OperatingIncomeLoss
-23269
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2803999
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-114342
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-47968
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
202928
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
10668347
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
298600
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
40340
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
10783433
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
578860
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1009107
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34452
us-gaap Revenues
Revenues
17257192
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
16004962
us-gaap Share Based Compensation
ShareBasedCompensation
821416
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10914524
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
204729 shares
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
-50023
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8546110 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8546110 shares
ccel Product Revenue
ProductRevenue
286253
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
-15111
ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
0
us-gaap Adjustment For Amortization
AdjustmentForAmortization
171689
dei Amendment Flag
AmendmentFlag
false
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
709000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
96869
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
25936
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1167202
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1696560
us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
89000
us-gaap Cost Of Services
CostOfServices
5085538
us-gaap Costs And Expenses
CostsAndExpenses
15148707
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
us-gaap Depreciation And Amortization
DepreciationAndAmortization
96925
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
73512
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Type
DocumentType
10-Q
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
dei Document Period End Date
DocumentPeriodEndDate
2017-08-31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
dei Entity Registrant Name
EntityRegistrantName
CRYO CELL INTERNATIONAL INC
dei Entity Central Index Key
EntityCentralIndexKey
0000862692
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>Product Warranty and Cryo-Cell Cares<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">TM</sup> Program</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February&#xA0;1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients. Effective June&#xA0;5, 2017, the Company increased the $75,000 payment warranty to a $100,000 payment warranty to all of its new clients that enroll in the Company&#x2019;s premium product, PrepaCyte CB. Clients that enroll in the standard product will receive a $75,000 payment warranty. Additionally, under the Cryo-Cell CaresTM program, the Company will pay $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloblative transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties. The Company does not maintain insurance for this warranty program and therefore maintains reserves to cover any estimated potential liabilities. The Company&#x2019;s reserve balance is based on the $100,000, $75,000 or $50,000 (as applicable) maximum payment and the $10,000 maximum expense reimbursement multiplied by formulas to determine the projected number of units requiring a payout. The Company determined the estimated expected usage and engraftment failure rates based on an analysis of the historical usage and failure rates and the historical usage and failure rates in other private and public cord blood banks based on published data. The Company&#x2019;s estimates of expected usage and engraftment failure could change as a result of changes in actual usage rates or failure rates and such changes would require an adjustment to the established reserves. The historical usage and failure rates have been very low and a small increase in the number of transplants or engraftment failures could cause a significant increase in the estimated rates used in determining the Company&#x2019;s reserve. In addition, the reserve will increase as additional umbilical cord blood specimens are stored which are subject to the warranty. As of August&#xA0;31, 2017 and November&#xA0;30, 2016 the Company recorded reserves under these programs in the amounts of approximately $18,000 and $17,000, respectively, which are included in accrued expenses in the accompanying consolidated balance sheets.</p> </div>
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2671172
us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
1039000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
805398
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-727969
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-25385
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
10560
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
613584 shares
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2763894
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1128012
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-122237
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
104669
us-gaap Interest Expense
InterestExpense
937248
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
446554
us-gaap Interest Expense Debt
InterestExpenseDebt
349685
us-gaap Licenses Revenue
LicensesRevenue
820877
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
105841
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
3606585
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-2545224
us-gaap Net Income Loss
NetIncomeLoss
1635882
us-gaap Operating Income Loss
OperatingIncomeLoss
3760609
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-996715
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
60678
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-59467
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-161023
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
446621
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
55182
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
51396
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-2876
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23682
us-gaap Revenues
Revenues
18909316
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2149999
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
17746408
us-gaap Share Based Compensation
ShareBasedCompensation
709173
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P4Y4M28D
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9942562
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.25
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
22500 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
34374 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
1.92
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
22500 shares
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
-60425
us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
Open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
dei Trading Symbol
TradingSymbol
CCEL
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7663366 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7049782 shares
ccel Product Revenue
ProductRevenue
342031
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
3388
ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
96869
ccel Description On Second Amendment To Employment Agreement
DescriptionOnSecondAmendmentToEmploymentAgreement
The Amendment provides for the grant of shares of the Company's common stock based on certain performance measures being attained by the Company during fiscal year 2016. The Amendment states if Executive is employed by the Company on November 30, 2016, then no later than February 28, 2017, the Company will grant Executive up to 20,000 shares of restricted stock based on performance as set forth in the Amendment.
ccel Contracted Storage Period Option Three
ContractedStoragePeriodOptionThree
Lifetime
ccel Types Of License Agreements
TypesOfLicenseAgreements
2 Agreement
ccel Number Of Deliverables For Revenue Recognized
NumberOfDeliverablesForRevenueRecognized
2 Deliverables
ccel Contracted Storage Period Option Two
ContractedStoragePeriodOptionTwo
P21Y
ccel Deferred Revenue Recognition Period
DeferredRevenueRecognitionPeriod
P12M
CY2017Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
103735
CY2017Q3 us-gaap Licenses Revenue
LicensesRevenue
492208
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
652019
ccel Period For Doubtful Of Accounts Receivable Due From Client
PeriodForDoubtfulOfAccountsReceivableDueFromClient
P21Y
ccel Contracted Storage Period Option One
ContractedStoragePeriodOptionOne
P1Y
ccel Minimum Percentage Probability Of Realized Tax Benefit On Settlement
MinimumPercentageProbabilityOfRealizedTaxBenefitOnSettlement
0.50 pure
CY2015Q2 ccel Tender Offer To Purchase Common Stock Price Per Share
TenderOfferToPurchaseCommonStockPricePerShare
3.25
CY2015Q2 ccel Tender Offer Sales Price
TenderOfferSalesPrice
2.29
CY2015Q2 ccel Percentage Of Outstanding Common Shares Purchases Under Tender Offer
PercentageOfOutstandingCommonSharesPurchasesUnderTenderOffer
0.0776 pure
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
238000
CY2017Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8646
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
686057
CY2017Q3 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
53000
CY2017Q3 us-gaap Cost Of Services
CostOfServices
1977475
CY2017Q3 us-gaap Costs And Expenses
CostsAndExpenses
5443708
CY2017Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
33359
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2017Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2017Q3 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
437000
CY2017Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
694623 shares
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1452233
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-309656
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1142577
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
490558
CY2017Q3 us-gaap Interest Expense
InterestExpense
314890
CY2017Q3 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
134162
CY2017Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
34038
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5234
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
226
CY2017Q3 us-gaap Revenues
Revenues
6895941
CY2017Q3 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
6288357
CY2017Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3432648
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
22500 shares
CY2017Q3 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2017Q3 us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
4784
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7794855 shares
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7100232 shares
CY2017Q3 ccel Product Revenue
ProductRevenue
115376
CY2017Q3 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
30427
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
433000
CY2016Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
12902
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2658483
CY2016Q3 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
91000
CY2016Q3 us-gaap Cost Of Services
CostOfServices
1551231
CY2016Q3 us-gaap Costs And Expenses
CostsAndExpenses
7394013
CY2016Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
39746
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2016Q3 us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
-2252388
CY2016Q3 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
1877697
CY2016Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2016Q3 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
-990000
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3543199
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-898838
CY2016Q3 us-gaap Interest Expense
InterestExpense
199439
CY2016Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
0
CY2016Q3 us-gaap Licenses Revenue
LicensesRevenue
609045
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-2644361
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1062075
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2481124
CY2016Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-14122
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-29297
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13780
CY2016Q3 us-gaap Revenues
Revenues
6331938
CY2016Q3 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
5634758
CY2016Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3911559
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
35000 shares
CY2016Q3 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2016Q3 us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
-29371
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7583771 shares
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7583771 shares
CY2016Q3 ccel Product Revenue
ProductRevenue
88135
CY2016Q3 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
0

Files In Submission

Name View Source Status
0001193125-17-310883-index-headers.html Edgar Link pending
0001193125-17-310883-index.html Edgar Link pending
0001193125-17-310883.txt Edgar Link pending
0001193125-17-310883-xbrl.zip Edgar Link pending
ccel-20170831.xml Edgar Link completed
ccel-20170831.xsd Edgar Link pending
ccel-20170831_cal.xml Edgar Link unprocessable
ccel-20170831_def.xml Edgar Link unprocessable
ccel-20170831_lab.xml Edgar Link unprocessable
ccel-20170831_pre.xml Edgar Link unprocessable
d452521d10q.htm Edgar Link pending
d452521dex311.htm Edgar Link pending
d452521dex312.htm Edgar Link pending
d452521dex313.htm Edgar Link pending
d452521dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending